Prior authorization for behavioral health and rehab therapy, visit cap aware

Behavioral and rehab PA share one thing: the treatment course is longer than the initial authorization, so most of the operational work is re-authorization at visit-cap boundaries. A patient in outpatient psychotherapy gets authorized for 8-12 sessions, then re-authorized. A patient in PT for a knee gets 6-8 visits, then re-authorized. A patient on TMS gets an authorized course of 30-36 sessions. The automation target is the renewal calendar, not the initial PA.

Psychiatry and outpatient therapy

Routine outpatient psychotherapy (90832, 90834, 90837) and medication management (99213-99215 with E/M coding) rarely require upfront PA for commercial plans under federal parity law. Some MBHOs require notification or concurrent review after a visit threshold. Medication PA for psychotropics is mostly handled through the PBM: stimulants (Adderall, Vyvanse, Concerta), atypical antipsychotics (Vraylar, Rexulti, Abilify), long-acting injectables (Invega Sustenna/Trinza, Aristada, Abilify Maintena), and newer antidepressants (Auvelity, Spravato esketamine).

Spravato (esketamine, J3490 or specific NDC) has a REMS program and site-of-care requirements. PA requires treatment-resistant depression documentation with failed trials of adequate duration and dose on two or more antidepressants. Session-by-session documentation is required throughout the induction and maintenance phases.

TMS and ECT

Transcranial magnetic stimulation (90867, 90868, 90869) requires treatment-resistant depression documentation: failed trials of at least two antidepressants from different classes at adequate duration and dose, typically documented medication history with dates. Some plans also require a failed augmentation trial or adjunctive therapy. TMS course is typically 30-36 sessions, and the PA is typically for the entire course. Retreatment after relapse often requires documentation of prior TMS response.

ECT (90870) has higher PA intensity for outpatient settings and typically requires documentation of severe or psychotic depression, treatment resistance, or specific indications (catatonia, pregnant patient with severe depression). Inpatient ECT follows inpatient psych PA rules.

Inpatient psych, partial hospitalization, residential

Inpatient psychiatric admission requires concurrent review almost universally. Initial admission is typically authorized for a short period (2-5 days) with ongoing concurrent review against InterQual Behavioral Health or MCG BH criteria. Partial hospitalization (PHP, H0035 or revenue code 912) and intensive outpatient (IOP, H0015 or revenue code 906) have their own authorization flows, typically 5-15 days initially with concurrent review. Residential treatment centers (RTC) have the strictest PA scrutiny with often prolonged clinical review and peer-to-peer.

Eating disorder levels of care (IP, RTC, PHP, IOP) typically route through specialized MBHO units (Optum Eating Disorders, Magellan specialty, Beacon specialty) with their own criteria sets.

SUD treatment and medication-assisted treatment

Substance use disorder PA splits across levels of care aligned with ASAM criteria: detox (ASAM 3.7-WM or 4), residential (ASAM 3.1, 3.3, 3.5), partial (ASAM 2.5), IOP (ASAM 2.1), outpatient (ASAM 1). Each level has PA requirements from the MBHO. Detox is usually short-auth with concurrent review. Residential and partial are the most PA-intensive with documented ASAM dimension scoring, medical and psychiatric comorbidity, and treatment history.

Medication-assisted treatment: methadone (H0020 or specific billing) through OTPs has a separate billing and PA structure. Buprenorphine (J0572-J0575 Sublocade, or PBM-billed Suboxone) has both medical-benefit injection PA and PBM-benefit oral PA. Naltrexone (Vivitrol J2315) requires SUD diagnosis and counseling engagement documentation. Most state Medicaid plans have SUD carve-out policies that differ from commercial plans.

PT, OT, and speech therapy

Physical therapy (evaluation 97161-97163, therapeutic exercise 97110, manual therapy 97140) PA is visit-cap driven. Commercial plans and MA plans typically authorize an initial 6-12 visits with progress notes required for re-authorization. OptumHealth MSK, Carelon Rehab, American Specialty Health (ASH), and eviCore MSK handle therapy PA for different payers. Medicare has a soft KX modifier threshold ($2,410 in 2024, indexed annually) after which additional documentation is required but not traditional PA.

Occupational therapy (97165-97168 eval, 97530 therapeutic activities, 97110 exercise) follows similar PA logic with visit-cap re-authorization. Hand therapy has additional specialty documentation requirements. Speech-language pathology (92507, 92521-92524 evaluation, 92526 swallowing treatment) shares the visit-cap pattern. Cognitive rehabilitation (97129, 97130) is newer and has tighter PA requirements at some plans.

Chiropractic

Chiropractic manipulative treatment (98940-98943) has narrow Medicare coverage (manual manipulation only, for documented subluxation) and variable commercial coverage with visit caps. ASH handles chiropractic network management and PA for several BCBS plans. Documentation of functional improvement and treatment plan is typically required for re-authorization.

MBHO delegates and carve-out rules

Behavioral and rehab EHRs

• Behavioral: Valant, TherapyNotes, SimplePractice, Qualifacts, Netsmart myAvatar, ICANotes, Credible. See therapy and behavioral EHRs.
• PT/OT/Speech: WebPT, Raintree, Prompt, TheraOffice, Net Health Therapy (Casamba).
• SUD/addiction: Kipu, Alleva, BestNotes.

How Flexbone handles behavioral and rehab PA

The visit-cap renewal pattern is the core automation target. Flexbone tracks visit counts against the authorized cap, triggers re-authorization when the cap approaches, pulls progress notes and functional-status scores from the EHR, and submits the renewal packet to the MBHO before the patient hits the cap. For inpatient and residential, Flexbone runs concurrent-review submissions on the review cadence. See PA workflow and the platform.